Patents by Inventor Jae Hoon Kang

Jae Hoon Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240262799
    Abstract: Disclosed are methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, disorder of bile acid homeostasis, or organ fibrosis, which includes administering to a subject a therapeutically effective amount of a pharmaceutical composition containing an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.
    Type: Application
    Filed: January 23, 2024
    Publication date: August 8, 2024
    Applicant: IL DONG PHARMACEUTICAL CO., LTD.
    Inventors: Jae-Hoon KANG, Hong-Sub LEE, Yoon-Suk LEE, Jin-Ah JEONG, Sung-Wook KWON, Jeong-Guen KIM, Kyung-Sun KIM, Dong-Keun SONG, Sun-Young PARK, Kyeo-Jin KIM, Ji-Hye CHOI, Hey-Min HWANG
  • Patent number: 11912674
    Abstract: The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: February 27, 2024
    Assignee: IL DONG PHARMACEUTICAL CO., LTD.
    Inventors: Jae-Hoon Kang, Hong-Sub Lee, Yoon-Suk Lee, Jin-Ah Jeong, Sung-Wook Kwon, Jeong-Guen Kim, Kyung-Sun Kim, Dong-Keun Song, Sun-Young Park, Kyeo-Jin Kim, Ji-Hye Choi, Hey-Min Hwang
  • Patent number: 11738064
    Abstract: The present invention relates to a pharmaceutical composition comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide is fused to an anti-vascular endothelial growth factor agent, methods of treating eye diseases with the pharmaceutical composition, and a method for preparing an anti-VEGF agent with an improved efficacy and ability to overcome resistance.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: August 29, 2023
    Assignee: ILDONG PHARM CO., LTD.
    Inventors: Seong Beom Kim, Hyei Yoon Jung, Seok Woo Yang, Hyuk Sang Kwon, Jae-Hoon Kang, Yong-Sung Kim
  • Patent number: 11731961
    Abstract: Compounds of Formula (I), racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions containing the compounds, racemates, enantiomers, diastereomers thereof are disclosed. These compounds have GPR40 agonist activity and are capable of modulating blood glucose levels and glucose-dependent insulin secretion mechanism, and, thus, exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. These compounds could be used in preventing and/or treating type 2 diabetes through adequate control of blood glucose.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: August 22, 2023
    Assignee: ILDONG PHARMACEUTICAL CO., LTD.
    Inventors: Jae-Hoon Kang, Hong-Sub Lee, Kyung-Mi An, Chang-Hee Hong, Hyun-Jung Kwak, Shuo-Lin Cui, Hyo-Jung Song
  • Publication number: 20220112185
    Abstract: Compounds of Formula (I), racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions containing the compounds, racemates, enantiomers, diastereomers thereof, and a manufacturing method thereof are disclosed. These compounds have GPR40 agonist activity and are capable of modulating blood glucose levels and glucose-dependent insulin secretion mechanism, and, thus, exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. These compounds could be used in preventing and/or treating type 2 diabetes through adequate control of blood glucose.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Applicant: ILDONG PHARMACEUTICAL CO., LTD.
    Inventors: Jae-Hoon KANG, Hong-Sub LEE, Kyung-Mi AN, Chang-Hee HONG, Hyun-Jung KWAK, Shuo-Lin CUI, Hyo-Jung SONG
  • Patent number: 11268064
    Abstract: The present invention relates to heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder, a preparation method therefor and a use thereof. The heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder of the present invention has an excellent therapeutic effect for atopic diseases, and particularly has high industrial applicability because membrane adhesion competitiveness, which is an advantage of existing lactic acid bacteria, is significantly improved, thereby exhibiting dermatitis preventing, alleviating and treating effects of the same level as steroid-based drugs.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: March 8, 2022
    Assignee: IL DONG PHARMACEUTICAL CO., LTD.
    Inventors: Seung-Hun Lee, Dae-Jung Kang, Jae-Hoon Kang
  • Publication number: 20220064154
    Abstract: Compounds of Formula (I), racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions containing the compounds, racemates, enantiomers, diastereomers thereof are disclosed. These compounds have GPR40 agonist activity and are capable of modulating blood glucose levels and glucose-dependent insulin secretion mechanism, and, thus, exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. These compounds could be used in preventing and/or treating type 2 diabetes through adequate control of blood glucose.
    Type: Application
    Filed: November 10, 2021
    Publication date: March 3, 2022
    Applicant: ILDONG PHARMACEUTICAL CO, LTD.
    Inventors: Jae-Hoon KANG, Hong-Sub LEE, Kyung-Mi AN, Chang-Hee HONG, Hyun-Jung KWAK, Shuo-Lin CUI, Hyo-Jung SONG
  • Patent number: 11225472
    Abstract: The present invention relates to the compounds according to Formula (I), the racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions comprising these, for the treatment or prevention of metabolic disorders. The compounds according to Formula (I) are, as GPR40 agonists, available for oral administration with glucose-dependent insulin secretion mechanism, which exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. Thus, the compounds and/or pharmaceutical compositions comprising the compounds as effective components are useful in treating and/or preventing symptoms of type 2 diabetes through adequate control of blood glucose.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: January 18, 2022
    Inventors: Jae-Hoon Kang, Hong-Sub Lee, Kyung-Mi An, Chang-Hee Hong, Hyun-Jung Kwak, Shuo-Lin Cui, Hyo-Jung Song
  • Publication number: 20210253657
    Abstract: A composition comprises, as an active ingredient, a fusion protein obtained by fusion of a tumor-penetrating peptide and an anti-angiogenic agent. The tumor-penetrating peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 5 to SEQ ID NO: 7.
    Type: Application
    Filed: May 3, 2021
    Publication date: August 19, 2021
    Inventors: Hyuk-Sang Kwon, Jong-Hee Ko, Young-Min Lee, Hyei-Yoon Jung, Seok-Woo Yang, Jae-Hoon Kang, Yong-Sung Kim
  • Publication number: 20210220436
    Abstract: The present invention relates to a pharmaceutical composition comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide is fused to an anti-vascular endothelial growth factor agent, methods of treating eye diseases with the pharmaceutical composition, and a method for preparing an anti-VEGF agent with an improved efficacy and ability to overcome resistance.
    Type: Application
    Filed: March 17, 2021
    Publication date: July 22, 2021
    Inventors: Seong Beom KIM, Hyei Yoon JUNG, Seok Woo YANG, Hyuk Sang KWON, Jae-Hoon KANG, Yong-Sung KIM
  • Patent number: 11052130
    Abstract: The present invention relates to a pharmaceutical composition comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide is fused to an anti-vascular endothelial growth factor agent, methods of treating eye diseases with the pharmaceutical composition, and a method for preparing an anti-VEGF agent with an improved efficacy and ability to overcome resistance.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: July 6, 2021
    Assignee: ILDONG PHARM CO., LTD.
    Inventors: Seong Beom Kim, Hyei Yoon Jung, Seok Woo Yang, Hyuk Sang Kwon, Jae-Hoon Kang, Yong-Sung Kim
  • Publication number: 20210188790
    Abstract: The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.
    Type: Application
    Filed: March 4, 2021
    Publication date: June 24, 2021
    Inventors: Jae-Hoon KANG, Hong-Sub Lee, Yoon-Suk Lee, Jin-Ah Jeong, Sung-Wook Kwon, Jeong-Guen Kim, Kyung-Sun Kim, Dong-Keun Song, Sun-Young Park, Kyeo-Jin Kim, Ji-Hye Choi, Hey-Min Hwang
  • Patent number: 10988449
    Abstract: The present invention relates to isoxazole derivatives, including pharmaceutical compositions and for the preparation of isoxazole derivatives. And more particularly the present invention provided a pharmaceutical composition of isoxazole derivatives for activation of Farnesoid X receptor (FXR, NR1H4).
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: April 27, 2021
    Assignee: IL DONG Pharmaceutical Co., Ltd.
    Inventors: Jae-Hoon Kang, Hong-Sub Lee, Yoon-Suk Lee, Jin-Ah Jeong, Sung-Wook Kwon, Jeong-Guen Kim, Kyung-Sun Kim, Dong-Keun Song, Sun-Young Park, Kyeo-Jin Kim, Ji-Hye Choi, Hey-Min Hwang
  • Patent number: 10919947
    Abstract: The present invention relates to a pharmaceutical composition containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial cell growth factor (anti-VEGF) agent are fused, for treating cancer or angiogenesis-related diseases. More specifically, the present invention relates to a use of the fusion protein for treating cancer or angiogenesis-related diseases, wherein the fusion protein improves the tissue penetrability of an anti-vascular endothelial cell growth factor agent and exerts a cancer targeting effect, thereby producing an excellent angiogenesis inhibiting effect and exhibiting a therapeutic effect on cancer showing resistance or unresponsiveness to the anti-VEGF agent.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: February 16, 2021
    Assignee: IL DONG PHARMACEUTICAL CO., LTD.
    Inventors: Hyuk-Sang Kwon, Jong-Hee Ko, Young-Min Lee, Hyei-Yoon Jung, Seok-Woo Yang, Jae-Hoon Kang, Yong-Sung Kim
  • Patent number: 10894086
    Abstract: The present invention relates to a functional hydrated hyaluronic acid and a method for producing 5th generation coated lactic acid bacteria having excellent intestinal mucoadhesive ability and a selective antagonism using the same and, more specifically, to a functional hydrated hyaluronic acid in which components fermented by lactic acid bacteria are captured in hyaluronic acid, which is a natural polymer substance, and a method for producing coated lactic acid bacteria using the same. The quadruply coated lactic acid bacteria coated using the functional hydrated hyaluronic acid according to the present invention is quadruply coated with a water-soluble polymer, a functional hydrated hyaluronic acid, a coating agent having porous particles, and a protein, thereby producing an excellent intestinal mucoadhesive ability, exhibiting an antibacterial action against deleterious bacteria in the intestines, and promoting growth of beneficial bacteria in the intestines.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: January 19, 2021
    Assignee: ILDONG PHARMACEUTICAL CO., LTD.
    Inventors: Seung-Hun Lee, Dae Jung Kang, Jae-Hoon Kang
  • Publication number: 20200223833
    Abstract: The present invention relates to the compounds according to Formula (1), the racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions comprising these, for the treatment or prevention of metabolic disorders. The compounds according to Formula (1) are, as GPR40 agonists, available for oral administration with glucose-dependent insulin secretion mechanism, which exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. Thus, the compounds and/or pharmaceutical compositions comprising the compounds as effective components are useful in treating and/or preventing symptoms of type 2 diabetes through adequate control of blood glucose.
    Type: Application
    Filed: December 14, 2017
    Publication date: July 16, 2020
    Inventors: Jae-Hoon Kang, Hong-Sub Lee, Kyung-Mi An, Chang-Hee Hong, Hyun-Jung Kwak, Shuo-Lin Cui, Hyo-Jung Song
  • Patent number: 10711345
    Abstract: The present invention relates to a hard coating including an MT-TiCN layer and an ?-alumina layer which are formed by using a chemical vapor deposition method. A hard coating for cutting tools, which is a coating formed on a base material of a cutting tool formed of a hard material, the coating comprising: a TiCN layer; and an ?-alumina layer formed on the TiCN layer, wherein: the ?-alumina layer has a main peak (maximal strength peak) of (006) plane located between 20-40 degrees during a psi rocking analysis by an XRD; a residual stress in the ?-Al2O3 layer is ?0.9-0.4 GPa; the TiCN layer is composed of TiCxNyOz (x+y+z?1, x>0, y>0, z?0); a composition ratio of C/(C+N) is greater than or equal to 0.4 and smaller than 0.5; the ratio of TC(220)/TC(422) is smaller than 0.45; and the ratio of TC(220)/TC(311) is less than 0.45.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: July 14, 2020
    Assignee: KORLOY INC.
    Inventors: Seong-woo Cho, Dong-youl Lee, Jae-hoon Kang, Soon-yong Hong, Sun-yong Ahn, Young-heum Kim
  • Publication number: 20200115349
    Abstract: The present invention relates to isoxazole derivatives, including pharmaceutical compositions and for the preparation of isoxazole derivatives. And more particularly the present invention provided a pharmaceutical composition of isoxazole derivatives for activation of Farnesoid X receptor (FXR, NR1H4).
    Type: Application
    Filed: April 12, 2018
    Publication date: April 16, 2020
    Inventors: Jae-Hoon KANG, Hong-Sub LEE, Yoon-Suk LEE, Jin-Ah JEONG, Sung-Wook KWON, Jeong-Guen KIM, Kyung-Sun KIM, Dong-Keun SONG, Sun-Young PARK, Kyeo-Jin KIM, Ji-Hye CHOI, Hey-Min HWANG
  • Publication number: 20190390159
    Abstract: The present invention relates to heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder, a preparation method therefor and a use thereof. The heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder of the present invention has an excellent therapeutic effect for atopic diseases, and particularly has high industrial applicability because membrane adhesion competitiveness, which is an advantage of existing lactic acid bacteria, is significantly improved, thereby exhibiting dermatitis preventing, alleviating and treating effects of the same level as steroid-based drugs.
    Type: Application
    Filed: September 9, 2019
    Publication date: December 26, 2019
    Inventors: Seung-Hun Lee, Dae-Jung Kang, Jae-Hoon Kang
  • Patent number: RE49338
    Abstract: The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: December 20, 2022
    Assignee: IDIENCE CO., LTD.
    Inventors: Jae-Hoon Kang, Hong-Sub Lee, Yoon-Suk Lee, Joon-Tae Park, Kyung-Mi An, Jin-Ah Jeong, Kyung-Sun Kim, Jeong-Geun Kim, Chang-Hee Hong, Sun-Young Park, Dong-Keun Song, Yong-Don Yun